Watch Clinical Laserthermia Systems AB (publ) for free: we tell you when fair value or trend changes.

Clinical Laserthermia Systems AB (publ) (CLS-B) fair value: what the stock is really worth

As of Oct 20, 2026: fair value (intrinsic value) of Clinical Laserthermia Systems AB (publ) stock SEK 0.57, price SEK 1.79, upside -68.2%, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · SE · ISIN SE0002756130

Thin data Oct 13, 2026

Clinical Laserthermia Systems AB (publ)

CLS-B · ST

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 68% below what the stock costs today.

Low debt

Mixed Growth (revenue 5y +67.4 %/yr in SEK)

Fair value kr 0.5695 · Strongly overvalued (−68.2%)

Quality 30/100

Negative free cash flow

Trails peers (2/9)

Narrow moat 6/100 · thin data

Thin data

⚠ Dilution

26 models, one by oneBear kr 0.3740 to bull kr 0.7055 Growth analysisrevenue history, year by year Quality 30/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Clinical Laserthermia Systems AB (publ) for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 13, 2026.

How to read this chart

60‑month range kr 1.75 – kr 327.90 · fair‑value band kr 0.3740 – kr 0.7055 · the kr 1.79 price screens above the kr 0.5695 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 13, 2026.

Follow Clinical Laserthermia Systems AB (publ) in your weekly email

Every Wednesday you see whether Clinical Laserthermia Systems AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue.

Show moreShow less

The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices.

The company has a strategic partnership with ClearPoint Neuro Inc. for the development of ClearPoint Prism, a Neuro Laser Therapy System. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

Stock analysis

Clinical Laserthermia Systems AB (publ) (CLS-B) currently trades at kr 1.79, while our model-based Fair Value estimate is kr 0.5695, 68.2% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the data coverage at low.

Scenario range: kr 0.3740 (bear) to kr 0.7055 (bull), the price of kr 1.79 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Clinical Laserthermia Systems AB (publ) reported revenue of 17.5M SEK in FY2025 versus 2.2M SEK in FY2021, a compound +67.1%/yr. Reported net income was −41.6M SEK in FY2025.

Key figures

Market cap 86.8M SEK (≈ $8.8M) Micro · P/S ratio 6.78 · EPS (TTM) kr −1.30 · Return on equity −73.3% · Return on assets (EBIT) −89.7% · Operating margin −91.4% · Revenue (TTM) 12.6M SEK · Revenue growth (YoY) −18.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 82% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −68%, CLS-B screens richer than that median.

Fair Value models

Bear kr 0.3740 Fair Value kr 0.5695 Bull kr 0.7055

Price kr 1.79 · Upside -68.2%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

NCAV (Graham) kr 0.4400 kr 0.6700 kr 0.8300 55

All 1 models by family

Asset-Based

NCAV (Graham) kr 0.4400 kr 0.6700 kr 0.8300 55

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1

How much profit the company makes from its sales and capital

Quality Growth 49

Are margins and returns getting better?

Cashflow 7

Do the profits arrive as real cash?

Financial strength 98

Debt, balance sheet and risk of trouble

Investment 16

Does it invest with discipline instead of growing at any price?

Low Volatility 50

How calm the share price moves, does not count

Momentum 13

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 0

Distance to the 52-week high, does not count

New shares 0

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

−6.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+40.8%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+67.4%

Start year 2020 (pandemic)

Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+32.3%

’10

’11

’12

’16

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−3,911.1% (2020) → −165.8% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

CLS-B screens overvalued: fair value 68% below the price. Compare with Abbott Laboratories, →

Compare Clinical Laserthermia Systems AB (publ) with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 325 stocks

Beats the industry median on 2/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 30 · Bottom 25%

Fair Value upside −68.2% · Bottom 25%

Profitability

Return on assets −54.4% · Bottom 25%

Operating margin (12 months) −91.4% · Bottom 25%

Growth and dividend

Revenue growth (quarter YoY) −18.3% · Bottom 25%

Balance sheet

Debt / equity 0.00× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.25× · Cheaper than median

P/S (12 months) 6.92× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 11

FUTURE (revenue growth)0 · sector 35

PAST (return on equity)0 · sector 16

HEALTH (low debt)100 · sector 98

DIVIDEND (yield)0 · sector 37

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Stryker Corporation SYK	$282.60	$310.86	+10%	vs CLS-B
Boston Scientific Corporation BSX	$43.00	$47.30	+10%	vs CLS-B
DexCom, Inc DXCM	$85.98	$94.58	+10%	vs CLS-B
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥166.00	¥182.60	+10%	vs CLS-B
GE HealthCare Technologies Inc GEHC	$65.74	$70.37	+7%	vs CLS-B
Edwards Lifesciences Corporation EW	$86.60	$81.94	−5%	vs CLS-B
Siemens Healthineers AG SHL	€41.45	€35.19	−15%	vs CLS-B
Abbott Laboratories, ABT	$102.61	$74.79	−27%	vs CLS-B
Medtronic plc MDT	$91.93	$65.61	−29%	vs CLS-B
Koninklijke Philips N.V PHIA	€22.18	€15.23	−31%	vs CLS-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Clinical Laserthermia Systems AB (publ) · Fair Value
kr 0.5695 −68%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/CLS-B" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Clinical Laserthermia Systems AB (publ) · Fair Value</span><br><b style="font-size:20px">kr 0.5695</b> <span style="color:var(--red);font-weight:700;font-size:14px">−68%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Clinical Laserthermia Systems AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/CLS-B

Frequently asked questions

Is Clinical Laserthermia Systems AB (publ) (CLS-B) overvalued or undervalued?

As of Oct 13, 2026, our model estimates a fair value of kr 0.5695 versus a price of kr 1.79, about −68% upside (overvalued).

What is the fair value of CLS-B?

Our model-based fair value for Clinical Laserthermia Systems AB (publ) is kr 0.5695 (as of Oct 13, 2026), built from audited fundamentals. The current price: kr 1.79.

What is the quality score of CLS-B?

Clinical Laserthermia Systems AB (publ) has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Clinical Laserthermia Systems AB (publ) (CLS-B)?

Our model-based price target is the fair value of kr 0.5695 (as of Oct 13, 2026) from 1 valuation models. Cautious scenario kr 0.3740, optimistic scenario kr 0.7055. It is a calculation from audited fundamentals, not an analyst target.

What is the Clinical Laserthermia Systems AB (publ) stock forecast for 2026?

Our models put fair value at kr 0.5695, about −68% upside versus a price of kr 1.79 (overvalued). Cautious scenario kr 0.3740, optimistic scenario kr 0.7055. The calculation is refreshed regularly with new filings.

What is the revenue of Clinical Laserthermia Systems AB (publ) (CLS-B)?

Clinical Laserthermia Systems AB (publ) reported trailing-twelve-month revenue of about 12.6M SEK (latest available figure, as of Oct 13, 2026).

What is the intrinsic value of Clinical Laserthermia Systems AB (publ) (CLS-B)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Clinical Laserthermia Systems AB (publ) it is kr 0.5695 per share (as of Oct 13, 2026), against a price of kr 1.79. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Clinical Laserthermia Systems AB (publ) stock overvalued or undervalued in 2026?

As of Oct 13, 2026, CLS-B trades above its calculated fair value: price kr 1.79, fair value kr 0.5695, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of CLS-B?

No. The price is what the market pays today (kr 1.79); the fair value is what the company's own numbers justify (kr 0.5695). For Clinical Laserthermia Systems AB (publ) the two are kr 1.22 per share apart. That gap is exactly why we show both numbers side by side.

How much is Clinical Laserthermia Systems AB (publ) worth?

The market values Clinical Laserthermia Systems AB (publ) at about 86.8M SEK (market capitalisation, as of Oct 13, 2026). Per share that is kr 1.79; our models calculate a fair value of kr 0.5695 per share.

What do the bullish and bearish scenarios say about CLS-B?

Our models span a range for Clinical Laserthermia Systems AB (publ): cautious scenario kr 0.3740, base kr 0.5695, optimistic kr 0.7055 per share (as of Oct 13, 2026, price kr 1.79). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Clinical Laserthermia Systems AB (publ) (CLS-B)?

Balance-sheet figures for Clinical Laserthermia Systems AB (publ) (as of Oct 13, 2026): return on equity −73.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.

How far is CLS-B from its 52-week high?

Clinical Laserthermia Systems AB (publ) trades at kr 1.79, about 82% below its 52-week high of kr 9.95 and 2% above the low of kr 1.75 (as of Oct 20, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.5695 is for.

Which stocks are comparable to Clinical Laserthermia Systems AB (publ)?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Clinical Laserthermia Systems AB (publ) stock attractive at the current price?

The data as of Oct 13, 2026: price kr 1.79, calculated fair value kr 0.5695 (−68%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of CLS-B calculated?

We run Clinical Laserthermia Systems AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.5695, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.9 % above its aggregate fair value. Clinical Laserthermia Systems AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Clinical Laserthermia Systems AB (publ) (CLS-B)?

The closing price on Oct 20, 2026 was kr 1.79. Our model-based fair value is kr 0.5695, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Clinical Laserthermia Systems AB (publ) right now?

The price sits above even our optimistic bull case (kr 0.7055). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.3740 to kr 0.7055) leaves room in how you read the outcome.

Key figures of Clinical Laserthermia Systems AB (publ)

How large is the market capitalisation of Clinical Laserthermia Systems AB (publ) (CLS-B)?

The market capitalisation of Clinical Laserthermia Systems AB (publ) is 86.8M SEK (≈ $8.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Clinical Laserthermia Systems AB (publ) (CLS-B)?

The price-to-sales ratio of Clinical Laserthermia Systems AB (publ) is 6.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Clinical Laserthermia Systems AB (publ) (CLS-B)?

Earnings per share at Clinical Laserthermia Systems AB (publ) are kr −1.30. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Clinical Laserthermia Systems AB (publ) (CLS-B)?

The return on equity (ROE) of Clinical Laserthermia Systems AB (publ) is −73.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Clinical Laserthermia Systems AB (publ) (CLS-B)?

On an EBIT basis the return on assets of Clinical Laserthermia Systems AB (publ) is −89.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Clinical Laserthermia Systems AB (publ) (CLS-B)?

The operating margin of Clinical Laserthermia Systems AB (publ) is −91.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Clinical Laserthermia Systems AB (publ) (CLS-B)?

Revenue at Clinical Laserthermia Systems AB (publ) is growing −18.3% versus a year earlier (3y avg +40.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Clinical Laserthermia Systems AB (publ) (CLS-B) generate?

The free cash flow of Clinical Laserthermia Systems AB (publ) is −35.9M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Clinical Laserthermia Systems AB (publ) (CLS-B) hold?

Clinical Laserthermia Systems AB (publ) holds more cash than debt, 21.5M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Clinical Laserthermia Systems AB (publ) in the live analysis

One click puts Clinical Laserthermia Systems AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.